Pharmacological descriptors related to the binding of Gp120 to CD4 corresponding to 60 representative HIV-1 strains

References

• Hartley O, Klasse PJ, Sattentau QJ, Moore JP. V3: HIV’s switch-hitter. AIDS Res Hum Retroviruses 2005;21:171–189.
   PubMed Web of Science ®Google Scholar
• Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, Harrison SC. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005;433:834–841.
   PubMed Web of Science ®Google Scholar
• Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: Current approaches and future directions. Curr Opin Immunol 2010;22:358–366.
   PubMed Web of Science ®Google Scholar
• Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: Good news for an HIV-1 vaccine? Nat Med 2009;15:866–870.
   PubMed Web of Science ®Google Scholar
• Lin G, Nara PL. Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein. Curr HIV Res 2007;5:514–541.
   PubMed Web of Science ®Google Scholar
• Corti D, Langedijk JP, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 2010;5:e8805.
   PubMed Web of Science ®Google Scholar
• Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648–659.
   PubMed Web of Science ®Google Scholar
• Brown BK, Darden JM, Tovanabutra S, Oblander T, Frost J, Sanders-Buell E et al. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J Virol 2005;79:6089–6101.
   PubMed Web of Science ®Google Scholar
• Leonard JT, Roy K. Exploring molecular shape analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors. Eur J Med Chem 2008;43:81–92.
   PubMed Web of Science ®Google Scholar
• Richards FM. The interpretation of protein structures: Total volume, group volume distributions and packing density. J Mol Biol 1974;82:1–14.
   PubMed Web of Science ®Google Scholar
• Richmond TJ. Solvent accessible surface area and excluded volume in proteins. Analytical equations for overlapping spheres and implications for the hydrophobic effect. J Mol Biol 1984;178:63–89.
   PubMed Web of Science ®Google Scholar
• Reorganizing the protein space at the Universal Protein Resource (UniProt). Nucleic Acids Res 2012;40:D71–D75.
   PubMed Web of Science ®Google Scholar
• Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Sayers EW. GenBank. Nucleic Acids Res 2011;39:D32–D37.
   PubMed Web of Science ®Google Scholar
• Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005;310:1025–1028.
   PubMed Web of Science ®Google Scholar
• Guilhaudis L, Jacobs A, Caffrey M. Solution structure of the HIV gp120 C5 domain. Eur J Biochem 2002;269:4860–4867.
   PubMedGoogle Scholar
• Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ. Jalview Version 2–a multiple sequence alignment editor and analysis workbench. Bioinformatics 2009;25:1189–1191.
   PubMed Web of Science ®Google Scholar
• Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993;234:779–815.
   PubMed Web of Science ®Google Scholar
• Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007;445:732–737.
   PubMed Web of Science ®Google Scholar
• Xiang SH, Kwong PD, Gupta R, Rizzuto CD, Casper DJ, Wyatt R et al. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 2002;76:9888–9899.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. CHARMM: A Program for macromolecular energy, minimization, and dynamics calculations. J Comp Chem 1983;4:187–217.
   Web of Science ®Google Scholar
• Humphrey W, Dalke A, Schulten K. VMD: Visual molecular dynamics. J Mol Graph 1996;14:33–8, 27.
   PubMed Web of Science ®Google Scholar
• Im W, Beglov D, Roux B. Continuum solvation model: Computation of electrostatic forces from numerical solutions to the Poisson-Boltzmann equation. Comput Phys Comm 1998;111:59–75.
   Web of Science ®Google Scholar
• Mackerell AD Jr, Feig M, Brooks CL 3rd. Extending the treatment of backbone energetics in protein force fields: Limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J Comput Chem 2004;25:1400–1415.
   PubMed Web of Science ®Google Scholar
• Levy Y, Onuchic JN. Water and proteins: A love-hate relationship. Proc Natl Acad Sci USA 2004;101:3325–3326.
   PubMed Web of Science ®Google Scholar